Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $82
Oppenheimer analyst Jay Olson maintains Prothena Corp (NASDAQ:PRTA) with a Outperform and raises the price target from $76 to $82.
Recap: Prothena Corp Q2 Earnings
Shares of Prothena Corp (NASDAQ:PRTA) rose in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 187.88% year over year to $0.58, which beat the estimate of $0.55.
Prothena Corp Q2 EPS $0.58 Beats $0.55 Estimate, Sales $60.07M Beat $58.77M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.55 by 5.45 percent. This is a 187.88 percent increase over losses of $(0.66) per share from the
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
Prothena Highlights Presentation Of New Data From Alzheimer’s Portfolio At Alzheimer’s Association International Conference 2021
Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with
Prothena To Present Data From Two Of Its Alzheimer’s Disease Programs At Alzheimer’s Association International Conference 2021 Jul. 26
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present
Where Prothena Corp Stands With Analysts
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
RBC Capital Maintains Outperform on Prothena Corp, Raises Price Target to $59
RBC Capital analyst Kennen MacKay maintains Prothena Corp (NASDAQ:PRTA) with a Outperform and raises the price target from $50 to $59.
Novo Nordisk To Buy Prothena’s ATTR Amyloidosis Program For Up To $1.2B
Novo Nordisk A/S (NYSE:NVO) will acquire Prothena Corporation plc’s (NASDAQ:PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is…
64 Biggest Movers From Friday
Gainers
Sentage Holdings Inc. (NASDAQ: SNTG) shares surged 597.8% to settle at $34.89 on Friday as the company priced its IPO at $5 per share.